The largest pharmaceutical companies donated almost twice as much money to patient advocacy groups in 2015 as they spent on federal lobbying, according to a Kaiser Health News investigation.
The big picture: Critics say drug company money could skew the views and priorities of patient groups, many of which have been silent on rising drug prices.